Caricamento quotazioni...
Previsioni
| Acquista |
4 |
| Mantieni |
9 |
| Vendi |
0 |
Notizie Vai al feed delle notizie
Satsuma Technologie announces auditor change after strategic review
Satsuma Technologie said that Kreston Reeves LLP has resigned its appointment following discussions as part of a comprehensive strategic review and the appointment of a new leadership team in summer 2025. The board has launched a formal selection process for a new auditor to support the company’s growth plans. A statement from Kreston Reeves on its resignation will be circulated and published in accordance with the Companies Act 2006, and a new appointment will be announced in due course. » Altro su de.investing.com
Satsuma Technologie raises £163.6 million through successful convertible bond issuance
Satsuma Technologie has raised £163.6 million by placing a second secured convertible bond, significantly surpassing its minimum target. The financing attracted prominent investors and allowed some to invest in Bitcoin instead of cash. The funds will be used for business expansion and to strengthen the company's Bitcoin-based treasury strategy. » Altro su de.investing.com
Tao Alpha becomes Satsuma Technology and adopts new ticker SATS.L
Tao Alpha PLC is changing its name to Satsuma Technology PLC and adopting the new ticker symbol SATS.L on the London Stock Exchange. The rebranding is intended to highlight the company's focus on decentralized AI services and a Bitcoin-based treasury strategy, while existing shareholder rights remain unaffected. CEO Matthew Lodge emphasizes that this marks a step into a new phase of operational maturity. » Altro su de.investing.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | 2022 | |
|---|---|---|
| Ricavi | 0,00 | - |
| Utile lordo | 0,00 | - |
| Utile netto | −64,48M | 43,02% |
| EBITDA | −54,36M | 22,13% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 31,30M€ |
Numero di azioni | 33,15M |
Massimo/minimo a 52 settimane | 6,94€ - 0,51€ |
| Dividendi | No |
Beta | 0,1 |
Rapporto P/E | −0,51 |
Rapporto PEG | 0,05 |
Rapporto P/B | −0,17 |
Rapporto P/S | 0,00 |
Profilo aziendale
Satsuma Pharmaceuticals, Inc. ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das neuartige therapeutische Produkte für die akute Behandlung von Migräne entwickelt. Der führende Produktkandidat des Unternehmens ist STS101, eine Arzneimittel-Geräte-Kombination aus einer patentrechtlich geschützten Trockenpulverformulierung von Dihydroergotaminmesylat, die sich in SUMMIT-Phase-3-Wirksamkeitsstudien befindet und mit einem patentrechtlich geschützten, vorgefüllten Einweg- und Nasenspritzgerät selbst verabreicht werden kann. Satsuma Pharmaceuticals, Inc. wurde im Jahr 2016 gegründet und hat seinen Hauptsitz in South San Francisco, Kalifornien.
| Nome | Satsuma Pharmaceuticals |
| CEO | John A. Kollins MBA |
| Sede centrale | South San Francisco,
ca Stati Uniti |
| Sito web | |
| Settore | Materiali |
| Industria | Prodotti chimici |
| Quotazione in borsa | 13/09/2019 |
| Dipendenti | 25 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | STSA |
Scopri gli asset
Gli azionisti di Satsuma Pharmaceuticals investono anche nei seguenti asset



